Free Trial

Autolus Therapeutics (AUTL) News Today

Autolus Therapeutics logo
$2.22 0.00 (0.00%)
As of 01/17/2025 04:00 PM Eastern
Autolus Therapeutics plc stock logo
JPMorgan Chase & Co. Has $4.66 Million Stake in Autolus Therapeutics plc (NASDAQ:AUTL)
JPMorgan Chase & Co. grew its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 145.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,284,708 shares of the company's stock after purchasing an
Autolus Therapeutics presents clinical data updates at Tandem Meetings
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.6% - Here's What Happened
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.6% - Time to Sell?
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday.
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Shares Up 5% - Time to Buy?
Autolus Therapeutics (NASDAQ:AUTL) Shares Up 5% - What's Next?
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Time to Buy?
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's Why
Autolus Therapeutics plc stock logo
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update
Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 7,680,000 shares, an increase of 22.1% from the November 30th total of 6,290,000 shares. Based on an average daily trading volume, of 1,750,000 shares, the days-to-cover ratio is presently 4.4 days.
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Sets New 52-Week Low - Time to Sell?
Autolus Therapeutics (NASDAQ:AUTL) Hits New 1-Year Low - Here's What Happened
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Time to Sell?
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Here's What Happened
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Hits New 12-Month Low - What's Next?
Autolus Therapeutics (NASDAQ:AUTL) Hits New 1-Year Low - Here's What Happened
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 4.4% - Time to Sell?
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.4% - Here's Why
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low - Here's Why
Autolus Therapeutics (NASDAQ:AUTL) Sets New 52-Week Low - Here's What Happened
Autolus Therapeutics plc stock logo
Wellington Management Group LLP Acquires 6,330,392 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)
Wellington Management Group LLP grew its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 35.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,220,226 shares of the company's stock after buying an add
Autolus Therapeutics plc stock logo
Fmr LLC Acquires 5,478,706 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)
Fmr LLC boosted its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 44.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,773,873 shares of the company's stock after a
Autolus Therapeutics plc stock logo
Erste Asset Management GmbH Makes New $708,000 Investment in Autolus Therapeutics plc (NASDAQ:AUTL)
Erste Asset Management GmbH purchased a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 195,000 shares of the company's stock, valued at approx
Autolus Therapeutics announces publication of data from FELIX study
Autolus Therapeutics plc stock logo
Great Point Partners LLC Has $10.21 Million Position in Autolus Therapeutics plc (NASDAQ:AUTL)
Great Point Partners LLC decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 18.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,811,955 shares of the company's stock after selling
Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's Why
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - What's Next?
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $7.00 to $7.60 in a research report on Monday.
Autolus Therapeutics plc stock logo
298,086 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Acquired by GSA Capital Partners LLP
GSA Capital Partners LLP bought a new position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 298,086 shares of the company's stock, valued at approximately $1,082,000
Autolus Therapeutics upgraded to Buy from Neutral at Redburn Atlantic
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Trading Up 4% - Still a Buy?
Autolus Therapeutics (NASDAQ:AUTL) Trading 4% Higher - Should You Buy?
Autolus Therapeutics plc stock logo
Autolus Therapeutics (NASDAQ:AUTL) Upgraded to Buy at Redburn Atlantic
Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price on the stock in a report on Friday.
Autolus Therapeutics plc stock logo
Equities Analysts Set Expectations for AUTL FY2024 Earnings
Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Research analysts at William Blair cut their FY2024 EPS estimates for shares of Autolus Therapeutics in a note issued to investors on Tuesday, November 12th. William Blair analyst M. Phipps now forecasts that the company will post earnings of
Autolus Therapeutics Q3 2024 Financial Update and FDA Approval
Autolus Therapeutics Wins FDA Approval for AUCATZYL®
Get Autolus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

AUTL Media Mentions By Week

AUTL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AUTL
News Sentiment

0.43

0.68

Average
Medical
News Sentiment

AUTL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AUTL Articles
This Week

12

4

AUTL Articles
Average Week

Get Autolus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AUTL) was last updated on 1/18/2025 by MarketBeat.com Staff
From Our Partners